b-Amyloid cleaving enzyme-1 (BACE1) has become a significant target for the therapy of Alzheimer’s disease. After the discovery of the first non-peptidomimetic b-secretase inhibitors by Takeda Chemicals in 2001, several research teams focused on SAR development of these agents. The non-peptidic BACE1 inhibitors may potentially overcome the classical problems associated with the peptide structure of first generation, such as blood–brain barrier crossing, poor oral bioavailability and susceptibility to P-glycoprotein transport. In the past 6 years a boom in research of non-peptidic BACE1 inhibitors has disseminated findings over hundreds of publications and patents. The rapidly growing literature has been reviewed with particular emphasis on literature of pharmaceutical companies.

Boom in the development of non-peptidic beta-secretase (BACE1) inhibitors for the treatment of Alzheimer's disease / Silvestri, Romano. - In: MEDICINAL RESEARCH REVIEWS. - ISSN 0198-6325. - STAMPA. - 29:(2009), pp. 295-338. [10.1002/med.20132]

Boom in the development of non-peptidic beta-secretase (BACE1) inhibitors for the treatment of Alzheimer's disease

SILVESTRI, Romano
2009

Abstract

b-Amyloid cleaving enzyme-1 (BACE1) has become a significant target for the therapy of Alzheimer’s disease. After the discovery of the first non-peptidomimetic b-secretase inhibitors by Takeda Chemicals in 2001, several research teams focused on SAR development of these agents. The non-peptidic BACE1 inhibitors may potentially overcome the classical problems associated with the peptide structure of first generation, such as blood–brain barrier crossing, poor oral bioavailability and susceptibility to P-glycoprotein transport. In the past 6 years a boom in research of non-peptidic BACE1 inhibitors has disseminated findings over hundreds of publications and patents. The rapidly growing literature has been reviewed with particular emphasis on literature of pharmaceutical companies.
2009
Alzheimer's disease; BACE-1 inhibitors
01 Pubblicazione su rivista::01a Articolo in rivista
Boom in the development of non-peptidic beta-secretase (BACE1) inhibitors for the treatment of Alzheimer's disease / Silvestri, Romano. - In: MEDICINAL RESEARCH REVIEWS. - ISSN 0198-6325. - STAMPA. - 29:(2009), pp. 295-338. [10.1002/med.20132]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/71628
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 22
  • Scopus 114
  • ???jsp.display-item.citation.isi??? 108
social impact